

7-5/2023/EU/WC-0552
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road
New Delhi-110002

Dated

21 MAR 2023

To

M/s. Shivalik Rasayan Limited,
Plot No. D-2/CH/41A, Dahej- II, Industrial Estate, Dahej,
Bharuch-392140, Gujarat, India

SUB:- Written Confirmation of M/s Shivalik Rasayan Limited, Plot No. D-2/CH/41A, Dahej- II, Industrial Estate, Dahej, Bharuch-392140, Gujarat, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application no. WC/FR/2022/4841 submitted to CDSCO, Ahmedabad Zonal office and the recommendation received from DDC(I), Ahmedabad Zonal office on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.

6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
-	06	21 MAR 2023	Three years from date of issue

Yours faithfully,


(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)



GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

WC-0552

CERTIFICATE NO. :

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: **M/s. Shivalik Rasayan Limited,
Plot No. D-2/CH/41A, Dahej- II, Industrial Estate,
Dahej, Bharuch-392140, Gujarat, India**

2. Manufacturer's licence number: : G/25/2374 & G/28/1746

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

List of API(s):

S. No.	Active substance(s)	Activity(ies)
1.	Azacitidine IH	Manufacturing & Packing
2.	Bortezomib IH	Manufacturing & Packing
3.	Busulfan BP/ EP/ USP	Manufacturing & Packing
4.	Dimethyl Fumarate IH	Manufacturing & Packing
5.	Pirfenidone EP	Manufacturing & Packing
6.	Temozolomide BP/ EP/ USP	Manufacturing & Packing

ITEM(S) Six (06) ONLY

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 15.03.2021 & 16.03.2021

The Written Confirmation remains valid until: Three years from the date of issue


The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: **Central Drugs Standard Control Organisation**
FDA Bhawan, Kotla Road,
New Delhi- 110 002, India

Name and function of responsible person: **Dr. Rajeev Singh Raghuvanshi,**
Drugs Controller General (India)

E-mail: **dci@nic.in,**
Telephone no.: **+91-11-23236965**
Fax no.: **+91-11-23236973**


Signature

21 MAR 2023

Stamp of the authority and date



7-5/2023/EU/WC-0552
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated

To

**M/s Shivalik Rasayan Limited,
Plot no. D-2/CH/41A, GIDC Industrial Estate,
Dahej II, Bharuch-392 140, Gujarat, India**

28 AUG 2023

SUB:- Written Confirmation of M/s Shivalik Rasayan Limited, Plot no. D-2/CH/41A, GIDC Industrial Estate, Dahej II, Bharuch-392 140, Gujarat, India for Three (03), as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your application number WC/ED/2023/7184 dated 06.06.2023 submitted to CDSCO, Ahmedabad Zone office, and the recommendation received from DDC(I), Ahmedabad Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.

6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
--	06	21.03.2023	20.03.2026
01	03	28 AUG 2023	20.03.2026

Yours faithfully,


(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)



GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

Annexure-01

CERTIFICATE NO. : WC-0552

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s Shivalik Rasayan Limited,
Plot no. D-2/CH/41A, GIDC Industrial Estate,
Dahej II, Bharuch-392 140, Gujarat, India


List of APIs:

Sr. No.	Active substance (s)	Activity(ies)
1.	Clonidine Hydrochloride IP/BP/EP/USP	Manufacturing & Packing
2.	Fingolimod Hydrochloride USP/EP	Manufacturing & Packing
3.	Pemetrexed Disodium Heptahydrate IP/BP/EP/USP	Manufacturing & Packing

ITEM(S) THREE(03) ONLY


This certificate is being issued subject to condition that the firm shall obtain NOC from the Competent Authority, on case to case basis, to manufacture active substance [Fingolimod Hydrochloride USP/EP] for the purpose of export only, as the above mentioned active substances are not approved for manufacture for sale in India.

The Written Confirmation remains valid until: 20.03.2026


Signature

28 AUG 2023

Stamp of the authority and date



7-5/2023/EU/WC-0552
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road,
New Delhi-110002

Dated: **28 FEB 2024**

To,

**M/s Shivalik Rasayan Limited,
Plot No. D-2/CH/41A, GIDC Industrial Estate,
Dahej II, Bharuch -392140, Gujarat, India**

SUB:- Written Confirmation of **M/s Shivalik Rasayan Limited, Plot No. D-2/CH/41A, GIDC Industrial Estate, Dahej II, Bharuch -392140, Gujarat, India**, as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application no. WC/FR/2023/7506 dated 29.08.2023 submitted to CDSCO, DDC(I), Ahmedabad Zone, and the recommendation received from DDC(I), Ahmedabad Zone, on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.

5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.
6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.
9. The manufacturer is required to comply with the provisions of GSR 20(E) dated 18.01.2022.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
--	06	21.03.2023	20.03.2026
01	03	28.08.2023	20.03.2026
02	02	28 FEB 2024	20.03.2026

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC


1. Name and address of site: M/s Shivalik Rasayan Limited,
Plot No. D-2/CH/41A, GIDC Industrial Estate,
Dahej II, Bharuch -392140, Gujarat, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
1.	Ambroxol Hydrochloride BP/IP/EP	Manufacturing & Packing
2.	Lenalidomide IH	Manufacturing & Packing

ITEM(S) TWO (02) ONLY

The Written Confirmation remains valid until: 20.03.2026

Signature 

Stamp of the authority and date



28 FEB 2024

7-5/2023/EU/WC-0552
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road,
New Delhi-110002

Dated

14 AUG 2024

To

M/s. Shivalik Rasayan Ltd,
Plot No. D-2/CH/41A, GIDC Industrial Estate,
Dahej II, Dist.-Bharuch-392140, Gujarat, India

SUBJECT: - Written Confirmation of M/s. Shivalik Rasayan Ltd, Plot No. D-2/CH/41A, GIDC Industrial Estate, Dahej II, Dist.-Bharuch-392140, Gujarat, India, as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application no. WC/ED/2024/8412 submitted to CDSCO, Gujarat Zonal office and the recommendation received from DDC (I), Gujarat Zonal office on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.


5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.
6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
7. In the event of any non-compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.
9. The manufacturer is required to comply with the provisions of GSR 20(E), dated 18.01.2022.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
--	06	21.03.2023	20.03.2026
01	03	28.08.2023	20.03.2026
02	02	28.02.2024	20.03.2026
03	02	14 AUG 2024	20.03.2026

Yours faithfully,


(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)



GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

Annexure-03
WC-0552

CERTIFICATE NO. :

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC


1. Name and address of site: M/s. Shivalik Rasayan Ltd,
Plot No. D-2/CH/41A, GIDC Industrial Estate,
Dahej II, Dist.-Bharuch-392140, Gujarat, India

List of APIs:

Sr. No.	Active substance (s)	Activity(ies)
1.	Palbociclib IH	Manufacturing & Packing
2.	Bendamustine Hydrochloride IP USP	Manufacturing & Packing

ITEM(S) TWO (02) ONLY

The Written Confirmation remains valid until: 20.03.2026


Signature



14 AUG 2024